MNMike A. Nalls

Mike A. Nalls

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mike A. Nalls has a total of 74 co-authors. Here are the top co-authors by number of shared publications:

  • Cornelis Blauwendraat

    Coalition for Aligning Sciences, Washington, DC, USA

    6 shared publications
  • Sara Bandres-Ciga

    Center for Alzheimer's and Related Dementias, National Institute on Aging, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA

    6 shared publications
  • Andrew B. Singleton

    Center for Alzheimer's and Related Dementias, National Institute on Aging, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA

    5 shared publications
  • Faraz Faghri

    Center for Alzheimer's and Related Dementias, National Institute on Aging, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA

    5 shared publications
  • Hirotaka Iwaki

    National Institutes of Health

    5 shared publications
  • Hampton L. Leonard

    Center for Alzheimer's and Related Dementias, NIH, Bethesda, MD

    3 shared publications

Latest Publications

  • Open Access

    A new AI assisted approach aligns data standards and accelerates interoperability in biomedical research

    by Rodney Alan Long, Shannon Ballard, Syed Shah, Owen Bianchi, Lietsel Jones, Mathew J. Koretsky, Nicole Kuznetsov, Elise Marsan, Bryant Jen, Philip Chiang, et al.

    We demonstrate how Large Language Models (LLMs) accelerate biomedical data harmonization through automated Common Data Element (CDE) generation. We processed 31 datasets including clinical taxonomies and research data dictionaries through OpenAI’s Generative Pre-trained Transformer - 4 (API Model gpt-4-0613), generating comprehensive metadata for each element using a template-based system. Subject-matter experts validated outputs, finding 94% of generated metadata fields required no revision overall, with an unweighted accuracy of 83.8%, unweighted, for semi-structured sources. Dramatically faster than manual approaches. Our system uses ElasticSearch with weighted field matching to identify semantic equivalences between variables, avoiding duplicate CDEs while building a standardized repository. Testing with Alzheimer’s Disease Neuroimaging Initiative (ADNI) and Global Parkinson’s Genetic Program (GP2) datasets showed 32.4% of previously unseen headers successfully mapped to our CDEs, with interoperability scores averaging 53.8/100 based on matching, completeness, and compliance metrics. This approach automates the most tedious aspects of data integration, reducing barriers to cross-study collaboration in biomedical research.


  • Open Access

    Assessing the lack of diversity in genetics research across neurodegenerative diseases: A systematic review of the GWAS Catalog and literature

    by Caroline Jonson, Kristin S. Levine, Julie Lake, Linnea Hertslet, Lietsel Jones, Dhairya Patel, Jeff Kim, Sara Bandres‐Ciga, Nancy Terry, Ignacio F. Mata, et al.

    The under‐representation of non‐European cohorts in neurodegenerative disease genome‐wide association studies (GWAS) hampers precision medicine efforts. Despite the inherent genetic and phenotypic diversity in these diseases, GWAS research consistently exhibits a disproportionate emphasis on participants of European ancestry. This study reviews GWAS up to 2022, focusing on non‐European or multi‐ancestry neurodegeneration studies. We conducted a systematic review of GWAS results and publications up to 2022, focusing on non‐European or multi‐ancestry neurodegeneration studies. Rigorous article inclusion and quality assessment methods were employed. Of 123 neurodegenerative disease (NDD) GWAS reviewed, 82% predominantly featured European ancestry participants. A single European study identified over 90 risk loci, compared to a total of 50 novel loci in identified in all non‐European or multi‐ancestry studies. Notably, only six of the loci have been replicated. The significant under‐representation of non‐European ancestries in NDD GWAS hinders comprehensive genetic understanding. Prioritizing genomic diversity in future research is crucial for advancing NDD therapies and understanding.Highlights: Eighty‐two percent of neurodegenerative genome‐wide association studies (GWAS) focus on Europeans. Only 6 of 50 novel neurodegenerative disease (NDD) genetic loci have been replicated. Lack of diversity significantly hampers understanding of NDDs. Increasing diversity in NDD genetic research is urgently required. New initiatives are aiming to enhance diversity in NDD research.


  • Open Access

    Assessing the lack of diversity in genetics research across neurodegenerative diseases: a systematic review of the GWAS Catalog and literature

    by Caroline Jonson, Kristin S. Levine, Julie Lake, Linnea Hertslet, Lietsel Jones, Dhairya Patel, Jeff Kim, Sara Bandres-Ciga, Nancy Terry, Ignacio F. Mata, et al.

    Importance: The under-representation of participants with non-European ancestry in genome-wide association studies (GWAS) is a critical issue that has significant implications, including hindering the progress of precision medicine initiatives. This issue is particularly significant in the context of neurodegenerative diseases (NDDs), where current therapeutic approaches have shown limited success. Addressing this under-representation is crucial to harnessing the full potential of genomic medicine in underserved communities and improving outcomes for NDD patients. Objective Our primary objective was to assess the representation of non-European ancestry participants in genetic discovery efforts related to NDDs. We aimed to quantify the extent of inclusion of diverse ancestry groups in NDD studies and determine the number of associated loci identified in more inclusive studies. Specifically, we sought to highlight the disparities in research efforts and outcomes between studies predominantly involving European ancestry participants and those deliberately targeting non-European or multi-ancestry populations across NDDs. Evidence Review: We conducted a systematic review utilizing existing GWAS results and publications to assess the inclusion of diverse ancestry groups in neurodegeneration and neurogenetics studies. Our search encompassed studies published up to the end of 2022, with a focus on identifying research that deliberately included non-European or multi-ancestry cohorts. We employed rigorous methods for the inclusion of identified articles and quality assessment. Findings Our review identified a total of 123 NDD GWAS. Strikingly, 82% of these studies predominantly featured participants of European ancestry. Endeavors specifically targeting non-European or multi-ancestry populations across NDDs identified only 52 risk loci. This contrasts with predominantly European studies, which reported over 90 risk loci for a single disease. Encouragingly, over 65% of these discoveries occurred in 2020 or later, indicating a recent increase in studies deliberately including non-European cohorts. Conclusions and relevance Our findings underscore the pressing need for increased diversity in neurodegenerative research. The significant under-representation of non-European ancestry participants in NDD GWAS limits our understanding of the genetic underpinnings of these diseases. To advance the field of neurodegenerative research and develop more effective therapies, it is imperative that future investigations prioritize and harness the genomic diversity present within and across global populations. Question What is the state of ancestral inclusivity in genetic studies of neurodegenerative diseases? Findings A systematic review of 123 publications on neurodegenerative diseases shows a focus on European populations, with only 18% of studies including any non-European ancestry data. Among 52 novel loci identified in non-European studies, 28 were from multi-ancestry studies (which included Europeans), 21 from East Asian studies, and 3 from other populations. Meaning This significant disparity underscores the need for more inclusive research approaches in neurodegenerative diseases, emphasizing multi-ancestry and non-European populations to advance precision medicine and develop treatments effective for diverse populations.


  • Open Access

    Sleep disturbances as risk factors for neurodegeneration later in life

    by Emily Simmonds, Kristin S. Levine, Jun Han, Hirotaka Iwaki, Mathew J. Koretsky, Nicole Kuznetsov, Faraz Faghri, Caroline Warly Solsberg, Artur Schuh, Lietsel Jones, et al.

    SUMMARY: The relationship between sleep disorders and neurodegeneration is complex and multi-faceted. Using over one million electronic health records (EHRs) from Wales, UK, and Finland, we mined biobank data to identify the relationships between sleep disorders and the subsequent manifestation of neurodegenerative diseases (NDDs) later in life. We then examined how these sleep disorders’ severity impacts neurodegeneration risk. Additionally, we investigated how sleep attributed risk may compensate for the lack of genetic risk factors (i.e. a lower polygenic risk score) in NDD manifestation. We found that sleep disorders such as sleep apnea were associated with the risk of Alzheimer’s disease (AD), amyotrophic lateral sclerosis, dementia, Parkinson’s disease (PD), and vascular dementia in three national scale biobanks, with hazard ratios (HRs) ranging from 1.31 for PD to 5.11 for dementia. These sleep disorders imparted significant risk up to 15 years before the onset of an NDD. Cumulative number of sleep disorders in the EHRs were associated with a higher risk of neurodegeneration for dementia and vascular dementia. Sleep related risk factors were independent of genetic risk for Alzheimer’s and Parkinson’s, potentially compensating for low genetic risk in overall disease etiology. There is a significant multiplicative interaction regarding the combined risk of sleep disorders and Parkinson’s disease. Poor sleep hygiene and sleep apnea are relatively modifiable risk factors with several treatment options, including CPAP and surgery, that could potentially reduce the risk of neurodegeneration. This is particularly interesting in how sleep related risk factors are significantly and independently enriched in manifesting NDD patients with low levels of genetic risk factors for these diseases. HIGHLIGHTS: Sleep disorders, particularly sleep apnea, are associated with the risk of Alzheimer’s disease, amyotrophic lateral sclerosis, dementia, Parkinson’s disease, and vascular dementia in national scale biobanks. These sleep disorders imparted significant risk up to 15 years before the onset of a neurodegenerative disease. The cumulative number of sleep disorders in the electronic health records were associated with a higher risk of neurodegeneration related to dementia and vascular dementia. Sleep related risk factors are independent of genetic risk for Alzheimer’s and Parkinson’s, potentially compensating for low genetic risk in overall disease etiology. Significant multiplicative interaction exists regarding the combined risk of sleep disorders and Parkinson’s disease.


  • Top Cited Papers
    Open Access

    Virus exposure and neurodegenerative disease risk across national biobanks

    by Kristin S. Levine, Hampton L. Leonard, Cornelis Blauwendraat, Hirotaka Iwaki, Nicholas Johnson, Sara Bandres-Ciga, Luigi Ferrucci, Faraz Faghri, Andrew B. Singleton, Mike A. Nalls


  • Open Access

    Virus exposure and neurodegenerative disease risk across national biobanks

    by Kristin Levine, Hampton L. Leonard, Cornelis Blauwendraat, Hirotaka Iwaki, Nicholas Johnson, Sara Bandres-Ciga, Walter Koroshetz, Luigi Ferrucci, Faraz Faghri, Andrew B. Singleton, et al.

    BACKGROUND With recent findings connecting Epstein-Barr virus to increased risk of multiple sclerosis and growing concerns regarding the potential neurological impact of the coronavirus pandemic, we surveyed biobank scale real-world data to identify potential links between viral exposures and neurodegenerative disease risks. METHODS To assess the potential increased risk of neurodegenerative diseases due to viral exposures, we mined time series data from FinnGen as a discovery dataset and cross-sectional data from the UK Biobank as a replication dataset for 73 pairs of common viral exposures and neurodegenerative disease outcomes. We investigated the impact of time span between viral exposure and disease risk using time series data from FinnGen at 1, 5, and 15 year intervals between exposure and disease onset. This analysis helped us to avoid the potential confounding of concurrent diagnosis due to hospitalization with viral infection. Further, to address the possible bias of reverse causality we examined risk for severe viral infections after NDD diagnosis. RESULTS We identified 45 viral exposures significantly associated with increased risk of post-exposure neurodegenerative disease onset after multiple test correction in the discovery phase using longitudinal data. 22 of these associations were replicated in cross sectional data from the UK Biobank. The largest effect association we saw replicated was between viral encephalitis exposure and Alzheimer’s disease, with discovery hazard estimates of ∼30 and a replication odds ratio of ∼22. We also replicated the association between Epstein-Barr virus exposure and multiple sclerosis 5-15 years before diagnosis of multiple sclerosis. In total, 17 virus/neurodegeneration pairs were significant with 5-15 years between viral exposure and NDD diagnosis. In an investigation of potential confounding and reverse causality, we generally see larger hazard ratios associated with viruses preceding NDD diagnosis than viruses post NDD diagnosis. CONCLUSIONS Viral exposures contribute to later in life risk of neurodegenerative disease with increased risk of neurodegeneration still significant at up to 15 years between some events in this report.


  • Open Access

    Evidence forGRNconnecting multiple neurodegenerative diseases

    by Mike A Nalls, Cornelis Blauwendraat, Lana Sargent, Dan Vitale, Hampton Leonard, Hirotaka Iwaki, Yeajin Song, Sara Bandres-Ciga, Kevin Menden, Faraz Faghri, et al.

    Previous research using genome-wide association studies has identified variants that may contribute to lifetime risk of multiple neurodegenerative diseases. However, whether there are common mechanisms that link neurodegenerative diseases is uncertain. Here, we focus on one gene, GRN, encoding progranulin, and the potential mechanistic interplay between genetic risk, gene expression in the brain and inflammation across multiple common neurodegenerative diseases. We utilized genome-wide association studies, expression quantitative trait locus mapping and Bayesian colocalization analyses to evaluate potential causal and mechanistic inferences. We integrate various molecular data types from public resources to infer disease connectivity and shared mechanisms using a data-driven process. Expression quantitative trait locus analyses combined with genome-wide association studies identified significant functional associations between increasing genetic risk in the GRN region and decreased expression of the gene in Parkinson’s, Alzheimer’s and amyotrophic lateral sclerosis. Additionally, colocalization analyses show a connection between blood-based inflammatory biomarkers relating to platelets and GRN expression in the frontal cortex. GRN expression mediates neuroinflammation function related to multiple neurodegenerative diseases. This analysis suggests shared mechanisms for Parkinson’s, Alzheimer’s and amyotrophic lateral sclerosis.


  • Open Access

    Evidence for GRN as part of a neuroinflammatory mechanism connecting common neurodegenerative diseases

    by Mike A. Nalls, Cornelis Blauwendraat, Lana Sargent, Dan Vitale, Hampton Leonard, Hirotaka Iwaki, Yeajin Song, Sara Bandres-Ciga, Kevin Menden, Faraz Faghri, et al.

    SUMMARY: Background: Previous research using genome wide association studies (GWAS) has identified variants that may contribute to lifetime risk of multiple neurodegenerative diseases. However, whether there are common mechanisms that link neurodegenerative diseases is uncertain. Here, we focus on one gene, GRN , encoding progranulin, and the potential mechanistic interplay between genetic risk, gene expression in the brain and inflammation across multiple common neurodegenerative diseases. Methods: We utilized GWAS, expression quantitative trait locus (eQTL) mapping and Bayesian colocalization analyses to evaluate potential causal and mechanistic inferences. We integrate various molecular data types from public resources to infer disease connectivity and shared mechanisms using a data driven process. Findings: eQTL analyses combined with GWAS identified significant functional associations between increasing genetic risk in the GRN region and decreased expression of the gene in Parkinson’s, Alzheimer’s and amyotrophic lateral sclerosis. Additionally, colocalization analyses show a connection between blood based inflammatory biomarkers relating to platelets and GRN expression in the frontal cortex. Interpretation: GRN expression mediates neuroinflammation function related to general neurodegeneration. This analysis suggests shared mechanisms for Parkinson’s, Alzheimer’s and amyotrophic lateral sclerosis. Funding: National Institute on Aging, National Institute of Neurological Disorders and Stroke, and the Michael J. Fox Foundation.